We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $156B
1-Year Est. Return 27.51%
This Fund
S&P 500
This Quarter Est. Return
+4%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.77%
AUM
$25B
AUM Growth
+$788M
Cap. Flow
-$383M
Cap. Flow %
-1.53%
Top 10 Hldgs %
6.32%
Holding
1,699
New
42
Increased
1,041
Reduced
462
Closed
65

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$106M
2
CERN
Cerner Corp
CERN
+$85.7M
3
BBWI icon
Bath & Body Works
BBWI
+$80.6M
4
HRL icon
Hormel Foods
HRL
+$80M
5
TOL icon
Toll Brothers
TOL
+$78.4M

Sector Composition

Rank Sector Weight
1 Financials 15.96%
2 Industrials 14.62%
3 Technology 12.79%
4 Consumer Discretionary 8.75%
5 Healthcare 8.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRVN
1576
DELISTED
Trevena, Inc.
TRVN
$14K ﹤0.01%
4
ADMS
1577
DELISTED
Adamas Pharmaceuticals
ADMS
$14K ﹤0.01%
935
+179
+24% +$2.95K
MINI
1578
DELISTED
Mobile Mini Inc
MINI
$14K ﹤0.01%
397
-1,484
-79% -$49.6K
CORI
1579
DELISTED
Corium International, Inc.
CORI
$14K ﹤0.01%
4,060
+690
+20% +$2.81K
AGEN
1580
Agenus
AGEN
$312M
$13K ﹤0.01%
163
+3
+2% +$234
CEMP
1581
DELISTED
Cempra, Inc.
CEMP
$13K ﹤0.01%
768
+15
+2% +$265
RLYP
1582
DELISTED
RELYPSA INC COM
RLYP
$13K ﹤0.01%
727
+330
+83% +$5.79K
BLUE
1583
DELISTED
bluebird bio
BLUE
$12K ﹤0.01%
22
+4
+22% +$2.27K
ACGN
1584
DELISTED
Aceragen Inc
ACGN
$12K ﹤0.01%
60
+9
+18% +$1.98K
CRIS icon
1585
Curis
CRIS
$9.78M
$11K ﹤0.01%
3
TGTX icon
1586
TG Therapeutics
TGTX
$7.96B
$11K ﹤0.01%
1,743
+274
+19% +$2.23K
FOMX
1587
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$11K ﹤0.01%
1,760
+70
+4% +$465
FTNT icon
1588
Fortinet
FTNT
$119B
$10K ﹤0.01%
1,565
KDNY
1589
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$10K ﹤0.01%
182
+36
+25% +$2.19K
QURE icon
1590
uniQure
QURE
$3.03B
$9K ﹤0.01%
1,174
+24
+2% +$287
CMRX
1591
DELISTED
Chimerix, Inc.
CMRX
$9K ﹤0.01%
2,355
-42,785
-95% -$211K
EXAS
1592
DELISTED
Exact Sciences
EXAS
$7K ﹤0.01%
545
+11
+2% +$83
CLDX icon
1593
Celldex Therapeutics
CLDX
$2.99B
$6K ﹤0.01%
91
+2
+2% +$127
TTPH
1594
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3K ﹤0.01%
32
+1
+3% +$92
NVTR
1595
DELISTED
Nuvectra Corporation Common Stock
NVTR
$3K ﹤0.01%
343
-273
-44% -$2.17K
ESPR
1596
DELISTED
Esperion Therapeutics
ESPR
$2K ﹤0.01%
242
+5
+2% +$83
STRA icon
1597
Strategic Education
STRA
$1.85B
$2K ﹤0.01%
+32
New +$1.51K
CLVS
1598
DELISTED
Clovis Oncology, Inc.
CLVS
$2K ﹤0.01%
161
+4
+3% +$58
AAOI icon
1599
Applied Optoelectronics
AAOI
$7.57B
-41,338
Closed -$616K
ANF icon
1600
Abercrombie & Fitch
ANF
$4.42B
-1,130,164
Closed -$35.6M

Similar funds

Victory Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Victory Capital Management held 1,699 positions worth $25B, up 3.3% from $24.2B the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.

Victory Capital Management's Q2 2016 filing shows 42 new, 1,041 increased, 462 reduced and 65 closed positions. Its largest new stake was PDC Energy, Inc.: 1,959,506 shares worth $113M. The largest sale was Perrigo, an estimated $106M.

By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 16% a quarter earlier, followed by Industrials and Technology.

  • Victory Capital Management's largest Q2 2016 buy was PDC Energy, Inc.: 1,959,506 shares worth $113M.
  • Victory Capital Management added most to Agilent Technologies in Q2 2016, an estimated $98.5M increase.
  • Victory Capital Management's biggest Q2 2016 reduction was Perrigo, cutting an estimated $106M.
  • Victory Capital Management fully exited Liberty Media Series C in Q2 2016, selling an estimated $68.4M.
  • Victory Capital Management's ten largest holdings make up 6.3% of its $25B portfolio in Q2 2016.
  • Victory Capital Management opened 42 new positions and closed 65 in Q2 2016.
  • Victory Capital Management's portfolio value rose 3.3% quarter-over-quarter to $25B.

Based on Victory Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.